This active fragment binds to neutrophil CR3, which then primes effector cells for the targeted killing of tumor cells through the activation of a CR3-Syk-Phosphatidylinositol-3-Kinase (PI3K) signaling pathway. Here, CRIPTO3 is linked to neoplasm.